Tag Archives: chemotherapy

Amgen drug extends survival in ovarian cancer study

* AMG 386 extends survival 1.6 mos vs chemotherapy alone * Amgen has launched Phase 3 trial LOS ANGELES Oct 9 (Reuters) – A mid-stage trial of an experimental drug … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine–Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review

Objective. To compare the tolerability, efficacy, and safety profiles of pegylated liposomal doxorubicin in combination with carboplatin (PLD–Carbo) with those of gemcitabine–carboplatin (Gem–Carbo) for the treatment of patients with platinum-sensitive … Continue reading 

Posted in News | Also tagged | Leave a comment

Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor Alpha, in Epithelial Ovarian Cancer: A Phase I Study

Purpose: Folate receptor alpha (FRα) expression is highly restricted in normal adult tissues, but upregulated in a wide range of human cancer types including epithelial ovarian cancer (EOC). Farletuzumab, a … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Impact of Shifting From Office- to Hospital-Based Treatment Facilities on the Administration of Intraperitoneal Chemotherapy for Ovarian Cancer

Introduction: Cancer chemotherapy in the United States has been delivered mostly in an office-based setting since the late 1980s. However, in the past 5 years, more patients have been treated … Continue reading 

Posted in News | Also tagged , | Leave a comment

Neoadjuvant Chemotherapy vs. Primary Surgery for Advanced Ovarian Cancer

Neoadjuvant chemotherapy followed by interval debulking was not inferior to the standard therapy of primary surgery followed by chemotherapy. Standard therapy for advanced ovarian cancer consists of primary debulking surgery … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.

BACKGROUND: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with … Continue reading 

Posted in News | Also tagged , , | Leave a comment

TGen finds protein inhibitor revives chemotherapy for ovarian patients

Investigators at the Translational Genomics Research Institute (TGen) have discovered a way that may help ovarian cancer patients who no longer respond to conventional chemotherapy. A scientific paper that will … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Roche’s Avastin helps slow ovarian cancer progression

* Second study backs up earlier late-stage trial Roche Holding AG’s (ROG.VX) cancer drug Avastin, in combination with chemotherapy, helps women with ovarian cancer live for longer without their disease … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Purpose The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

“Shielded” ovarian cancer cells may survive chemotherapy

Monday 28 June 2010 Cancer Research UK Press Release “SHIELDED” OVARIAN CANCER CELLS MAY SURVIVE CHEMOTHERAPY TO RE-GROW TUMOUR Cancer Research UK scientists have discovered certain ovarian tumour cells that … Continue reading 

Posted in News | Also tagged , | Leave a comment

Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer

BACKGROUND: Most women with advanced epithelial ovarian cancer will ultimately develop recurrent disease after completion of initial treatment with primary surgery and adjuvant chemotherapy. Secondary cytoreductive surgery may have survival … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment